Skip to main content

Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.

Objetivo

Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn. This chronic non-communicable disease is increasing at an alarming rate due to increasing European obesity, alcohol use and ageing. The three main causes of the disease; alcohol, fatty liver and viral hepatitis are amenable to prevention and treatment. Gut-derived endotoxins and bacterial translocation are central factors implicated in the pathogenesis of fatty liver disease and, the development and progression of cirrhosis. In cirrhosis, current state-of-the-art therapy to prevent recurrent complications of advanced cirrhosis is to use poorly absorbed antibiotics but long-term antibiotic therapy has problems associated with bacterial resistance, infection with resistant organisms and the cost. Treatment of fatty liver and modulation of bacterial translocation in early cirrhosis to prevent complications is an unmet need. Our academic-industrial consortium has developed a novel, patented, safe and cheap nanoporous carbon that modulates the effects of bacterial translocation in animal models of liver disease. Our feasibility studies demonstrate that this product advances the current state-of-the-art, is a TRL 4/5 and is now ready for validation through clinical trials. We propose to investigate the safety and efficacy of this novel nanoporous carbon in patients with fatty liver disease and cirrhosis. If successful, we will be able to confirm an innovative, cost-effective and novel strategy for the management of this chronic disease in a European population. Exploitation of the results of the CARBALIVE project will support the continued development of this carbon through additional private and public sector investment. The use of this innovative therapy is expected to reduce the economic burden of the disease in Europe, allow patients to achieve enhanced quality of life, improve survival, and allow many patients to return to economic productivity.

Convocatoria de propuestas

H2020-PHC-2014-two-stage
Consulte otros proyectos de esta convocatoria

Coordinador

UNIVERSITY COLLEGE LONDON
Dirección
Gower Street
WC1E 6BT London
United Kingdom
Tipo de actividad
Higher or Secondary Education Establishments
Aportación de la UE
€ 1 826 222,81

Participantes (14)

MAST CARBON INTERNATIONAL LTD

La participación finalizó

United Kingdom
Aportación de la UE
€ 398 495,13
Dirección
Jays Close Viables
RG22 4BA Basingstoke
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ALPHA BIORESEARCH, SL
España
Aportación de la UE
€ 598 250
Dirección
Calle Lopez De Hoyos 155 3 Puerta 6 7
28002 Madrid
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITY OF BRIGHTON
United Kingdom
Aportación de la UE
€ 178 750
Dirección
Lewes Road Mithras House
BN2 4AT Brighton
Tipo de actividad
Higher or Secondary Education Establishments
A2F ASSOCIATES LIMITED
United Kingdom
Aportación de la UE
€ 137 500
Dirección
7 Laureate Paddocks
CB8 0AP Newmarket
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
España
Aportación de la UE
€ 93 750
Dirección
Calle Rossello 149 Puerta Bjs
08036 Barcelona
Tipo de actividad
Other
UNIVERSITA DEGLI STUDI DI PADOVA

La participación finalizó

Italia
Aportación de la UE
€ 51 351,69
Dirección
Via 8 Febbraio 2
35122 Padova
Tipo de actividad
Higher or Secondary Education Establishments
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
España
Aportación de la UE
€ 93 750
Dirección
Passeig Vall D Hebron 119-129 Edificio De Recerca
08035 Barcelona
Tipo de actividad
Research Organisations
ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA
Italia
Aportación de la UE
€ 93 750
Dirección
Via Zamboni 33
40126 Bologna
Tipo de actividad
Higher or Secondary Education Establishments
FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA
Portugal
Aportación de la UE
€ 76 000
Dirección
Avenida Professor Egas Moniz, Edificio Hospital Santa Maria
1649-028 Lisboa
Tipo de actividad
Higher or Secondary Education Establishments
SERVICIO MADRILENO DE SALUD
España
Aportación de la UE
€ 93 750
Dirección
Plaza Carlos Trias Bertran 7
28020 Madrid
Tipo de actividad
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
UNIVERSITAET BERN
Suiza
Aportación de la UE
€ 0
Dirección
Hochschulstrasse 6
3012 Bern
Tipo de actividad
Higher or Secondary Education Establishments
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
Francia
Aportación de la UE
€ 18 277,19
Dirección
3 Avenue Victoria
75000 Paris
Tipo de actividad
Research Organisations
YAQRIT LIMITED
United Kingdom
Aportación de la UE
€ 2 170 732,93
Dirección
The Network Building 97 Tottenham Court Road
W1T 4TP London
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)
España
Aportación de la UE
€ 82 500
Dirección
Travessera De Gracia 11, 7Th Floor
08021 Barcelona
Tipo de actividad
Research Organisations